Features of ovarian cancer in Lynch syndrome (Review)
- Authors:
- Kanako Nakamura
- Kouji Banno
- Megumi Yanokura
- Miho Iida
- Masataka Adachi
- Kenta Masuda
- Arisa Ueki
- Yusuke Kobayashi
- Hiroyuki Nomura
- Akira Hirasawa
- Eiichiro Tominaga
- Daisuke Aoki
-
Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160‑8582, Japan - Published online on: August 20, 2014 https://doi.org/10.3892/mco.2014.397
- Pages: 909-916
This article is mentioned in:
Abstract
Crispens MA: Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg. 25:97–102. 2012. View Article : Google Scholar : PubMed/NCBI | |
Neesham D: Ovarian cancer screening. Aust Fam Physician. 36:126–128. 2007. | |
Lu KH: Clinical relevance of hereditary endometrial cancer. Hereditary gynecologic cancer: risk, prevention, and management. 1st edition. Informa Healthcare; New York, NY: pp. 15–28. 2008 | |
Bewtra C, Watson P, Conway T, Read-Hippee C and Lynch HT: Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 11:180–187. 1992. View Article : Google Scholar : PubMed/NCBI | |
Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 116:1453–1456. 1999. View Article : Google Scholar | |
Jascur T and Boland CR: Structure and function of the components of the human DNA mismatch repair system. lnt J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI | |
Harfe BD and Jinks-Robertson S: DNA mismatch repair and genetic instability. Annu Rev Genet. 34:359–399. 2000. View Article : Google Scholar : PubMed/NCBI | |
Kuiper RP, Vissers LE, Venkatachalam R, et al: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat. 32:407–414. 2011. View Article : Google Scholar : PubMed/NCBI | |
Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar | |
Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer. 81:214–218. 1999. View Article : Google Scholar : PubMed/NCBI | |
Watson P, Vasen HF, Menklin JP, et al: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 123:444–449. 2008. View Article : Google Scholar : PubMed/NCBI | |
Engel C, Loeffler M, Steinke V, et al: Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 30:4409–4415. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ketabi Z, Bartuma K, Bernstein I, et al: Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 121:462–465. 2011. View Article : Google Scholar : PubMed/NCBI | |
Watson P, Bützow R, Lynch HT, et al; International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 82:223–228. 2001. View Article : Google Scholar : PubMed/NCBI | |
Lu K: Gynecological malignancy as a ‘sentinel cancer’ for women with HNPCC. Gynecol Oncol. 92:4212004. | |
Vasen HF, Stormorken A, Menko FH, et al: MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 19:4074–4080. 2001.PubMed/NCBI | |
Cederquist K, Emanuelsson M, Wiklund F, Golovleva I, Palmqvist R and Grönberg H: Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet. 68:533–541. 2005. View Article : Google Scholar : PubMed/NCBI | |
Sood AK, Holmes R, Hendrix MJ and Buller RE: Application of the National Cancer Institute International criteria for determination of microsatellite instability in ovarian cancer. Cancer Res. 61:4371–4374. 2001.PubMed/NCBI | |
Gras E, Catasus L, Argüelles R, et al: Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer. 92:2829–2836. 2001. View Article : Google Scholar : PubMed/NCBI | |
Cai KQ, Albarracin C, Rosen D, et al: Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 35:552–559. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rosen DG, Cai KQ, Luthra R and Liu J: Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 19:1414–1420. 2006.PubMed/NCBI | |
Malander S, Rambech E, Kristoffersson U, et al: The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 101:238–243. 2006. View Article : Google Scholar : PubMed/NCBI | |
Domanska K, Malander S, Måsbäck A and Nilbert M: Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer. 17:789–793. 2007. View Article : Google Scholar : PubMed/NCBI | |
Shaw PA, McLaughlin JR, Zweemer RP, et al: Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 21:407–411. 2002. View Article : Google Scholar : PubMed/NCBI | |
Piek JM, Torrenga B, Hermsen B, et al: Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer. 2:73–78. 2003. View Article : Google Scholar : PubMed/NCBI | |
Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al: Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer. 4:301–305. 2005. View Article : Google Scholar : PubMed/NCBI | |
Watson P and Lynch HT: Cancer risk in mismatch repair gene mutation carriers. Fam Cancer. 1:57–60. 2001. View Article : Google Scholar : PubMed/NCBI | |
Grindedal EM, Renkonen-Sinisao L, Vasen H, et al: Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet. 47:99–102. 2010. View Article : Google Scholar : PubMed/NCBI | |
Aebi S, Kurdi-Haidar B, Gordon R, et al: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:3087–3090. 1996.PubMed/NCBI | |
Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLHl gene promoter. Cancer Res. 60:6039–6044. 2000. | |
Helleman J, van Staveren IL, Dinjens WN, et al: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 6:2012006. View Article : Google Scholar : PubMed/NCBI | |
Lindor NM, Petersen GM, Hadley DW, et al: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 296:1507–1517. 2006. View Article : Google Scholar : PubMed/NCBI | |
Brown GJ, St John DJ, Macrae FA and Aittomäki K: Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol. 80:346–349. 2001. View Article : Google Scholar : PubMed/NCBI | |
Zurawski VR Jr, Orjaseter H, Anderson A and Jellum E: Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 42:677–680. 1988. View Article : Google Scholar : PubMed/NCBI | |
Zurawski VR Jr, Sjovall K, Schoenfeld DA, et al: Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 36:299–305. 1990. View Article : Google Scholar | |
Skates SJ, Xu FJ, Yu YH, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 76(10 Suppl): 2004–2010. 1995. View Article : Google Scholar : PubMed/NCBI | |
Buys SS, Partridge E, Greene MH, et al; PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 193:1630–1639. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 306:1030–1034. 1993. View Article : Google Scholar : PubMed/NCBI | |
Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI | |
Jacobs IJ, Mackay J, Menon U, Skates SJ, Rosenthal AN and Fraser L: Familial ovarian screening - effective or ineffective? Br J Cancer. 95(1124): 1126–1127. 2006. View Article : Google Scholar : PubMed/NCBI | |
Partridge E, Kreimer AR, Buys S, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian Screening Trial: Results from 4 years of annual screening in a randomized trial. Gynecol Oncol. 104(Suppl 3): abstr 10. S2–S35. 2007. | |
Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium JAMA. 227:997–1003. 1997.PubMed/NCBI | |
Armstrong K, Micco E, Carney A, Stopfer J and Putt M: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 293:1729–1736. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rosenthal AN, Fraser L, Manchanda R, et al: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 31:49–57. 2013. View Article : Google Scholar | |
Burn J, Gerdes AM, Macrae F, et al; CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar | |
No authors listed. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and steroid Hormone Study. JAMA. 249:1600–1604. 1983. View Article : Google Scholar : PubMed/NCBI | |
No authors listed. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study for the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 316:650–655. 1987. View Article : Google Scholar : PubMed/NCBI | |
Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 339:424–428. 1998. View Article : Google Scholar : PubMed/NCBI | |
Tavani A, Ricci E, La Vecchia C, et al: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI | |
Whittemore AS, Balise RR, Pharoah PD, et al: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer. 91:1911–1915. 2004. View Article : Google Scholar : PubMed/NCBI | |
McLaughlin JR, Risch HA, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 8:26–34. 2007. View Article : Google Scholar : PubMed/NCBI | |
Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 277:915–919. 1997. View Article : Google Scholar : PubMed/NCBI | |
Bertagnolli MM: Surgical prevention of cancer. J Clin Oncol. 23:324–332. 2005. View Article : Google Scholar | |
Lynch HT, Watson P, Shaw TG, et al: Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer. Part II: Hereditary nonpolyposis colorectal carcinoma as a model. Cancer. 86(11 Suppl): 2457–2463. 1999. View Article : Google Scholar | |
Lu KH, Dinh M, Kolhmann W, et al: Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 105:569–574. 2005. | |
Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 354:261–269. 2006. View Article : Google Scholar : PubMed/NCBI | |
Banno K, Kisu I, Yanokura M, et al: Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome (Review). Int J Oncol. 41:793–797. 2012.PubMed/NCBI | |
Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG and Vasen HF: Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 102:198–200. 2002. View Article : Google Scholar : PubMed/NCBI | |
Chen LM, Yang KY, Little SE, Cheung MK and Caughey AB: Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol. 110:18–25. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:1609–1615. 2002. View Article : Google Scholar : PubMed/NCBI | |
Rebbeck TR, Lynch HT, Neuhausen SL, et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:1616–1622. 2002. View Article : Google Scholar : PubMed/NCBI | |
Schmeler KM, Daniels MS, Soliman PT, et al: Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol. 115:432–434. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF and Bardawil WA: Role of heredity in multiple primary cancer. Cancer. 40(4 Suppl): 1849–1854. 1977. View Article : Google Scholar : PubMed/NCBI | |
Parker WH, Broder MS, Liu Z, et al: Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 106:219–226. 2005. View Article : Google Scholar : PubMed/NCBI | |
Niskakoski A, Kaur S, Renkonen-Sinisalo L, et al: Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer. 133:2596–2608. 2013.PubMed/NCBI | |
Oda K: Targeting Ras-PI3K/mTOR pathway and predictive biomarkers in endometrial cancer. Gan To Kagaku Ryoho. 38:1084–1087. 2011.(In Japanese). | |
Costa-Guda J, Soong CP, Parekh VI, Agarwal SK and Arnold A: Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 4:301–307. 2013. View Article : Google Scholar : PubMed/NCBI | |
Jürgens B, Schmitz-Dräger BJ and Schulz WA: Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Cancer Res. 56:5698–5703. 1996.PubMed/NCBI | |
Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 41:664–668. 2004. View Article : Google Scholar : PubMed/NCBI | |
Woloszynska-Read A, Zhang W, Yu J, et al: Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 17:2170–2180. 2011. View Article : Google Scholar |